Login to Your Account



Financings Roundup


Wednesday, May 23, 2012
• Halo Therapeutics LLC, of Newton, Mass., received funding of $1.1 million from 12 nonprofit foundations dedicated to muscular dystrophy. Halo will use the funding to support its Phase II trial of HT-100 for Duchenne's muscular dystrophy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription